DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Phase 3

Recruiting

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Biological: Ianalumab
Drug: Placebo

First Posted Date: 2022-12-13

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT05648968

Locations: 🇺🇸
University of Colorado Anschutz, Aurora, Colorado, United States
🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States

and more 13 locations

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Phase 2

Recruiting

Conditions: Aortic Stenosis

Interventions: Drug: Pelacarsen (TQJ230) 80mg
Drug: Matching placebo

First Posted Date: 2022-12-12

Last Posted Date: 2025-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 502

Registration Number: NCT05646381

Locations: 🇺🇸
Heart Center Research Llc, Huntsville, Alabama, United States
🇺🇸
Cardiovascular Res Found, Beverly Hills, California, United States
🇺🇸
National Heart Institute, Beverly Hills, California, United States

and more 26 locations

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Ianalumab
Drug: Placebo

First Posted Date: 2022-12-06

Last Posted Date: 2025-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 406

Registration Number: NCT05639114

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Providence Medical Center, Burbank, California, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

and more 27 locations

Kesimpta (Ofatumumab) Pregnancy Registry

Recruiting

Conditions: Pregnancy
Multiple Sclerosis

Interventions: Other: Kesimpta

First Posted Date: 2022-12-02

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 725

Registration Number: NCT05634967

Locations: 🇺🇸
University of California San Diego OTIS, La Jolla, California, United States

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Phase 4

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant

First Posted Date: 2022-11-30

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05631795

Locations: 🇮🇳
Novartis Investigative Site, New Delhi, India

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Phase 3

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Iptacopan

First Posted Date: 2022-11-29

Last Posted Date: 2024-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT05630001

Locations: 🇺🇸
City Of Hope National Med Center, Duarte, California, United States
🇺🇸
Lakes Research, Miami Lakes, Florida, United States
🇺🇸
Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States

and more 7 locations

The 'Wearing Off' Effect of DMT

Completed

Conditions: Multiple Sclerosis

Interventions: Other: natalizumab
Other: ocrelizumab
Other: ofatumumab

First Posted Date: 2022-11-25

Last Posted Date: 2023-06-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT05627271

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

Active, not recruiting

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Other: Xolair

First Posted Date: 2022-11-23

Last Posted Date: 2025-03-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT05626257

Locations: 🇰🇷
Novartis Investigative Site, Suwon, Korea, Republic of

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: placebo
Drug: ianalumab

First Posted Date: 2022-11-22

Last Posted Date: 2025-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 280

Registration Number: NCT05624749

Locations: 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸
University of Calif Irvine Med Cntr, Irvine, California, United States
🇺🇸
Advanced Medical Research, La Palma, California, United States

and more 15 locations

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Phase 4

Recruiting

Conditions: Non-radiographic Axial Spondyloarthritis

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2022-11-21

Last Posted Date: 2025-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 340

Registration Number: NCT05622708

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy